Contextually, our FAT1 findings are, at least in part, corroborated by data indicating that the aberrant expression of the male-specific protocadherin-PC (PCDH-PC) in prostate cancer cells facilitate their acquisition of an apoptosis-evading and hormone therapy-resistant phenotype through enhanced nuclear accumulation of β-catenin and increased WNT-signaling [40]. The gene discussed is PCDH11X; the disease is Familial prostate cancer.